- Main shareholder dievini Hopp BioTech and the Federal Government agree on a landmark investment in a company in the innovative biotechnology sector for the first time
- Direct equity financing by the Federal Government is to be made by the Kreditanstalt für Wiederaufbau (KfW)
- mRNA company CureVac retains complete operational and strategic independence; the Federal Government will not influence corporate policy decisions
- It is a central step towards implementing the Corona Economic Stimulus and Future Technologies Package of the Federal Government from 03 June 2020
The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.
Details of the investment, which will be made by the Kreditanstalt für Wiederaufbau (KfW), have been laid out in a definitive draft agreement. The funds from the capital increase will be used by CureVac for the further development of the Company’s proprietary pipeline and mRNA platform technology and the expansion of business activities. Under the agreement, the KfW will hold a stake of around 23 percent in CureVac.curevac.com